KALA BIO

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for rare and severe diseases of the eye, leveraging the company's proprietary mesenchymal stem cell secretome-based technology platform. Following the May 8, 2026 1-for-50 reverse stock split (reducing outstanding shares to approximately 18.6M to address Nasdaq's $1.00 minimum bid price requirement), the company continues to operate under the KALA ticker. The January 2026 424B5 prospectus supplement established a $15M at-the-market common-stock program through H.C. Wainwright. KALA's pipeline targets ophthalmic indications with high unmet need including persistent corneal epithelial defect (PCED) and rare anterior segment inflammatory conditions.